Arecor Therapeutics (AREC) Insider Trading & Ownership GBX 49.30 +0.30 (+0.61%) As of 07/18/2025 08:42 AM Eastern Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock Arecor Therapeutics (LON:AREC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage25.34%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)£39.18KNumber OfInsiders Selling(Last 12 Months)0 Get AREC Insider Trade Alerts Want to know when executives and insiders are buying or selling Arecor Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AREC Insider Buying and Selling by Quarter Arecor Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/19/2025Andrew RichardsInsiderBuy31,750GBX 47£14,922.505/19/2025Sarah Jennifer HowellInsiderBuy21,077GBX 47£9,906.195/13/2025Andrew RichardsInsiderBuy35,000GBX 41£14,350 (Data available from 1/1/2013 forward) AREC Insider Trading Activity - Frequently Asked Questions Who is on Arecor Therapeutics' Insider Roster? The list of insiders at Arecor Therapeutics includes Andrew Richards, and Sarah Jennifer Howell. Learn more on insiders at AREC. What percentage of Arecor Therapeutics stock is owned by insiders? 25.34% of Arecor Therapeutics stock is owned by insiders. Learn more on AREC's insider holdings. Which Arecor Therapeutics insiders have been buying company stock? The following insiders have purchased AREC shares in the last 24 months: Andrew Richards (£29,272.50), and Sarah Jennifer Howell (£9,906.19). How much insider buying is happening at Arecor Therapeutics? Insiders have purchased a total of 87,827 AREC shares in the last 24 months for a total of £39,178.69 bought. Arecor Therapeutics Key ExecutivesDr. Sarah Jennifer Howell Ph.D. (Age 49)CEO & Director Compensation: $421k1 recent tradesMs. Susan Day Lowther FCMA (Age 64)CFO, Company Secretary & Director Compensation: $306kDr. Jan Jezek Ph.D.Chief Scientific OfficerMr. David GerringSenior Vice President of DevelopmentDr. Manjit Rahelu Ph.D.Chief Business Officer More Insider Trading Tools from MarketBeat Related Companies Sareum Insider Selling Poolbeg Pharma Insider Selling IXICO Insider Selling Fusion Antibodies Insider Selling Oxford BioDynamics Insider Selling Destiny Pharma Insider Selling Roquefort Therapeutics Insider Selling Oncimmune Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional SupportDo They Know Something? Insiders & Congress Buy UnitedHealth This page (LON:AREC) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
